Welcome to our dedicated page for UNITED THERAPEUTICS SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
UNITED THERAPEUTICS Corp CFO and Treasurer James Edgemond reported a series of insider transactions in the company’s common stock. On May 21, 2026, he exercised 10,000 stock options at an exercise price of $117.76 per share, converting them into common shares.
That same day, he executed multiple open-market sales totaling 10,000 shares at prices in the mid‑$560s, with trades reported at weighted average prices such as $566.12 and $563.12. The filing states these transactions were carried out under a Rule 10b5‑1 trading plan entered into on October 31, 2025, indicating they were pre‑scheduled.
After these transactions, Edgemond directly owns 18,876 shares of United Therapeutics common stock and holds 70,000 stock options following the 10,000‑share option exercise.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt reported option exercises and related share sales in United Therapeutics common stock. On 2026-05-21, she exercised 9,500 stock options at an exercise price of $146.03 per share, receiving an equal number of common shares.
That same day, she sold 9,500 common shares in multiple open-market transactions at weighted average prices generally between about $560 and $566, under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following these transactions, she directly held 40,513 common shares and also had additional indirect holdings through various family trusts and a spouse account.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt reported an option exercise and related share sales. On May 20, 2026, she exercised stock options for 9,500 shares of common stock at a strike price of $146.03 per share and sold 9,500 shares in multiple open-market transactions at prices generally in the $561–$578 range.
These trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of exercising 1,734,410 stock options expiring on March 17, 2027, or December 31, 2026. Following the transactions, she directly holds 40,513 common shares and also has indirect holdings through several family trusts and a spouse account.
UNITED THERAPEUTICS Corp executive Paul A. Mahon exercised stock options and sold shares of Common Stock in pre-planned trades. On May 21, 2026, the EVP & General Counsel exercised options covering 8,300 shares at a conversion price of $146.03 per share and sold 8,300 shares in multiple open-market transactions at weighted-average prices in the mid-$560s. These trades were executed pursuant to a pre-arranged Rule 10b5-1 trading plan entered into on August 11, 2025. After the transactions, Mahon directly holds 45,172 shares of UNITED THERAPEUTICS Common Stock.
UTHR affiliate files a Form 144 proposing the sale of 8,300 shares of Common Stock via a stock option exercise on 05/21/2026. The filing also lists five completed sales of 8,300 shares each on 05/07/2026, 04/16/2026, 04/02/2026, 03/19/2026, and 03/05/2026 with reported proceeds of $4,870,054.05, $4,787,596.87, $4,696,690.29, $4,398,610.73, and $4,010,187.33, respectively.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported an option exercise and related share sales. On May 19, 2026, she exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share and sold 9,500 shares in multiple open-market transactions at weighted average prices generally around $561–$572 per share. The filing states these trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of exercising 1,734,410 options expiring on March 17, 2027 or December 31, 2026. Rothblatt also reports indirect ownership of additional common shares through various family trusts and her spouse.
United Therapeutics CFO and Treasurer James Edgemond reported a combination of stock option exercises and share sales in the company’s common stock. On May 18, 2026, he exercised options for 10,000 shares at strike prices of $117.76 and $135.42 per share, then sold 10,000 shares in multiple open-market transactions at prices between approximately $562.91 and $570.18. The filing states these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan entered into on October 31, 2025, and he continues to hold United Therapeutics common stock following the activity.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported a combination of stock option exercise and pre-planned share sales. She exercised stock options covering 9,500 shares of common stock at a $146.03 exercise price and sold 9,500 shares in multiple open-market trades at weighted average prices around $565–$570 per share. These transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which allows up to the exercise of 1,734,410 stock options expiring on March 17, 2027, or runs until December 31, 2026, whichever occurs first. Following the reported transactions, she directly holds 40,513 shares of common stock, in addition to indirect holdings through family trusts and her spouse.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share and sold the resulting shares in multiple open-market transactions on May 15, 2026 under a pre-arranged Rule 10b5-1 trading plan.
Following these transactions, Rothblatt directly holds 40,513 shares of common stock and also has additional indirect holdings through various family trusts and a spouse account. The 10b5-1 plan, adopted on November 7, 2025, will continue until the earlier of the exercise of 1,734,410 stock options that expire on March 17, 2027 or December 31, 2026.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised stock options and sold the resulting common shares under a pre-arranged Rule 10b5-1 trading plan. She exercised 9,500 stock options at an exercise price of $146.03 per share and received an equal number of common shares.
On the same date, she sold 9,500 common shares in multiple open-market transactions at prices generally between about $570.51 and $578.68 per share, leaving 50,013 common shares held directly. Additional common shares are held indirectly through various family trusts and by her spouse, as disclosed in the footnotes.